Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area

• Published in: BMC cancer Vol. 19; no. 1; p. 37
• Main Authors: Yao, Ji-Jin, Zhu, Feng-Ting, Dong, Jun, Liang, Zi-Bin, Yang, Le-Wei, Chen, Shao-Yi, Zhang, Wang-Jian, Lawrence, Wayne R, Zhang, Fan, Wang, Si-Yang, Sun, Ying, Zhou, Guan-Qun
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.01.2019; BioMed Central; BMC
• Subjects: Apoptosis; Biomarkers; Cancer; Cancer diagnosis; Cancer metastasis; Cancer therapies; Carcinoma; Chemotherapy; Cohort analysis; Family medical history; Laboratories; Lymphocytes; Medical prognosis; Metastases; Metastasis; Multivariate analysis; Nasopharyngeal cancer; Nasopharyngeal carcinoma; Nasopharyngeal carcinoma, advanced; Neutrophil-to-lymphocyte ratio; Neutrophils; NMR; Nuclear magnetic resonance; Patients; Prognosis; Radiation therapy; Studies; Systematic review; Throat cancer; China; United States > US; Maryland; Neutrophil-to-lymphocyte ratio; Nasopharyngeal carcinoma, advanced; Prognosis
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-5236-2

Findings remain unclear whether neutrophil-to-lymphocyte ratio (NLR) detrimentally affects advanced nasopharyngeal carcinoma (NPC) prognosis. We aim to evaluate the prognostic value of NLR in patients with NPC based on a large-scale cohort from an endemic area. We selected patients retrospectively from a cohort examining long-term cancer outcomes following diagnosis. Neutrophil counts and lymphocyte counts were assessed prior to treatment. Kaplan-Meier method and log-rank test were used to calculate and compare survival outcomes. Additionally, Cox proportional hazards model was utilized to carry out univariate and multivariate analyses. Between October 2009 and August 2012, we enrolled 1550 consecutive NPC patients staged II-IVB. The median value of NLR was 2.27 (interquartile range [IQR], 1.71-3.12). Determined by operating characteristic curve using overall survival (OS) as an endpoint, the cutoff value for NLR was 2.50. At 5 years, NLR > 2.50 was associated with inferior OS (90.3% vs 82.5%; P < 0.001), distant metastasis-free survival (DMFS, 89.4% vs 85.0%; P = 0.014), and progression-free survival (PFS, 80.9% vs 76.5%; P = 0.031) than NLR ≤2.50. In multivariate analysis, NLR was found to be a significant prognostic factor for OS (HR, 1.72; 95% CI, 131-2.24; P < 0.001), DMFS (HR, 1.45; 95% CI, 1.10-1.92; P = 0.009), and PFS (HR, 1.29; 95% CI, 1.04-1.59; P = 0.021). Pretreatment NLR independently affects survival. Our findings suggest that NLR measurements will be of great clinical significance in the management of NPC.